Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dieter A Häring

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Pharmaceutical Statistics|October 23, 2018
Blinded continuous monitoring in clinical trials with recurrent event endpointsTim Friede, Dieter A Häring, Heinz Schmidli
Clinical Trials (London, England)|February 5, 2024
New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trialsMarc Vandemeulebroecke, Dieter A Häring, Eva Hua, et al.
Clinical Pharmacology and Therapeutics|November 15, 2019
Beyond Randomized Clinical Trials: Use of External ControlsHeinz Schmidli, Dieter A Häring, Marius Thomas, et al.
Neurology and Therapy|February 16, 2020
Correction to: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII TrialsAngelo Ghezzi, Tanuja Chitnis, Annik K-Laflamme, et al.
Neurology and Therapy|July 21, 2019
Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II TrialsAngelo Ghezzi, Tanuja Chitnis, Annik K-Laflamme, et al.
Neurology|March 16, 2018
Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosisLaura Gaetano, Dieter A Häring, Ernst-Wilhelm Radue, et al.
Neurology|April 5, 2022
Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled TrialsDavid Leppert, Harald Kropshofer, Dieter A Häring, et al.
European Journal of Neurology|August 25, 2021
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosisDawn W Langdon, Davorka Tomic, Iris-Katharina Penner, et al.
Journal of Comparative Effectiveness Research|October 22, 2020
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysisImtiaz A Samjoo, Evelyn Worthington, Christopher Drudge, et al.
Journal of Comparative Effectiveness Research|February 23, 2021
Efficacy classification of modern therapies in multiple sclerosisImtiaz A Samjoo, Evelyn Worthington, Christopher Drudge, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Pharmaceutical Statistics|October 23, 2018
Blinded continuous monitoring in clinical trials with recurrent event endpointsTim Friede, Dieter A Häring, Heinz Schmidli
Clinical Trials (London, England)|February 5, 2024
New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trialsMarc Vandemeulebroecke, Dieter A Häring, Eva Hua, et al.
Clinical Pharmacology and Therapeutics|November 15, 2019
Beyond Randomized Clinical Trials: Use of External ControlsHeinz Schmidli, Dieter A Häring, Marius Thomas, et al.
Neurology and Therapy|February 16, 2020
Correction to: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII TrialsAngelo Ghezzi, Tanuja Chitnis, Annik K-Laflamme, et al.
Neurology and Therapy|July 21, 2019
Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II TrialsAngelo Ghezzi, Tanuja Chitnis, Annik K-Laflamme, et al.
Neurology|March 16, 2018
Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosisLaura Gaetano, Dieter A Häring, Ernst-Wilhelm Radue, et al.
Neurology|April 5, 2022
Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled TrialsDavid Leppert, Harald Kropshofer, Dieter A Häring, et al.
European Journal of Neurology|August 25, 2021
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosisDawn W Langdon, Davorka Tomic, Iris-Katharina Penner, et al.
Journal of Comparative Effectiveness Research|October 22, 2020
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysisImtiaz A Samjoo, Evelyn Worthington, Christopher Drudge, et al.
Journal of Comparative Effectiveness Research|February 23, 2021
Efficacy classification of modern therapies in multiple sclerosisImtiaz A Samjoo, Evelyn Worthington, Christopher Drudge, et al.
Pageof 4